Valuation
- Market cap
- 3,677,000
- Revenue TTM
- $0
- Net income TTM
- $-26,980,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 118,300
- Avg volume
- 1,908,364
- Day's range
- $0.18 – $0.19
- Shares out
- 19,340,000
- Stochastic %K
- 48%
- Beta
- -2.40
- Analysts
- Strong Buy
- Price target
- $1.50
Company profile
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation envir...
Show more
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 781 996 5252
- Website
- https://www.kalarx.com
- Address
- 1167 Massachusetts Avenue, Arlington, United States
Latest news
No headlines yet.
